|
Key Signals · 3 trials updated
- Innate Pharma / LYSA | lacutamab | Phase 2 PTCL (NCT04984837) | RECRUITING → ACTIVE_NOT_RECRUITING at v8, 2026-06-02 (prior v7 2026-04-15 was RECRUITING); enrollment capped at ~56; readout clock now running for anti-KIR3DL2 in relapsed/refractory PTCL
- Novartis | pelabresib (DAK539) + ruxolitinib | Phase 3 MF (PPV-MF / PV-adjacent) (NCT07357727) | 3 consecutive Contacts/Locations updates (v8-10, June 1-3, 2026); rapid site expansion across global Phase 3 in post-polycythemia vera myelofibrosis
- Sanofi / Fred Hutchinson | belumosudil | Phase 2 pre-emptive cGvHD (NCT05996627) | Contacts/Locations updated v14, 2026-06-03; RECRUITING unchanged; likely site addition, no status change
- Novartis | rapcabtagene autoleucel | Phase 1/2 DLBCL/CLL/ALL (NCT03960840) | Contacts/Locations updated v45, 2026-06-03; ACTIVE_NOT_RECRUITING unchanged — likely location administrative refresh
- Golcadomide post-CAR-T Phase 2 (NCT06271057, LYSA/LSA) | RECRUITING, no status change; Merck zilovertamab vedotin Phase 2/3 rrDLBCL (NCT05139017) | RECRUITING, no status change — routine updates
|
|
Scan window: 2026-06-04 → 2026-06-05
MATERIAL
NCT04984837 — Innate Pharma / Lymphoma Academic Research Organisation | Lacutamab | Phase 2 | PTCL | STATUS TRANSITION
- Evidence: v8 (2026-06-02): OverallStatus → ACTIVE_NOT_RECRUITING; prior v7 (2026-04-15) was RECRUITING. Module labels at v8: "Study Status, Study Design, Contacts/Locations."
- Enrollment: ~56 participants (estimate capped per v8; v7 also showed enrollment constant)
- Indication: Peripheral T-cell Lymphoma (relapsed/refractory)
- Significance: Enrollment closure for the lacutamab (anti-KIR3DL2) Phase 2 in PTCL (LYSPTCL study) means full enrollment has been reached; a readout on efficacy in nodal PTCL should now be on the horizon. Innate Pharma is a tracked_sponsor.
NCT07357727 — Novartis | Pelabresib (DAK539) + Ruxolitinib | Phase 3 | MF (PPV-MF / PET-MF) | GEOGRAPHIC SITE EXPANSION
- Evidence: v8 (2026-06-01), v9 (2026-06-02), v10 (2026-06-03) — 3 consecutive versions all changed "Study Status, Contacts/Locations"; RECRUITING status unchanged.
- Enrollment: 460 participants | PCD: 2028-05-17
- Significance: Rapid back-to-back site additions in this global Novartis Phase 3 covering post-PV and post-ET myelofibrosis — a PV-adjacent indication in scope. Ruxolitinib (tracked molecule) is the backbone; pelabresib (BET bromodomain inhibitor) is not currently tracked in danbury scope. Novartis is a priority sponsor.
- Scope hygiene: Consider adding pelabresib (DAK539 / Novartis) to the danbury tracked_molecules list for PV/MF, given this active Phase 3.
NCT05996627 — Fred Hutchinson / Sanofi | Belumosudil | Phase 2 | Pre-emptive cGvHD | SITE ADDITION
- Evidence: v14 (2026-06-03): "Study Status, Contacts/Locations" changed; RECRUITING status maintained.
- Enrollment: 82 participants | PCD: 2028-04-30
- Significance: Ongoing site addition activity for belumosudil in pre-emptive cGvHD (treating before clinical diagnosis). Sanofi is a tracked_sponsor. Belumosudil is a tracked molecule.
NOISE / NOT PROMOTED
NCT04974216 (tafasitamab + lenalidomide + rituximab, DLBCL ≥80 y/o, LYSA): v6 (2026-06-02) changed only "Study Status, Contacts/Locations"; ACTIVE_NOT_RECRUITING status unchanged (same since v5, 2024-10-08). PCD 2024-07-15 is well past — no new status transition this cycle.
NCT03960840 (rapcabtagene autoleucel, Novartis, Phase 1/2 DLBCL/CLL/ALL): v45 (2026-06-03) changed "Study Status, Contacts/Locations"; ACTIVE_NOT_RECRUITING unchanged. Administrative location refresh; rapcabtagene is not in the danbury tracked_molecules list.
NCT07252050 (ruxolitinib-enhanced haplo HCT, Incyte collaborator): Sickle cell disease indication — outside danbury scope (PCNSL/PV/TCL/GvHD).
NCT06271057 (golcadomide post-CAR-T, LYSA/LSA) and NCT05139017 (zilovertamab vedotin, Merck): RECRUITING unchanged, no parameter changes; routine updates only.
|